Assessment of Therapeutic Response of Edaravone and Riluzole Combination Therapy in Amyotrophic Lateral Sclerosis Patients

BACKGROUND: Amyotrophic lateral sclerosis (ALS) is a progressive disease characterized by chronic degeneration of upper and lower motor neurons and finally death within 3–5 years usually because of respiratory failure. Riluzole and edaravone are presently available treatments. It may be better to tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Samadhiya, Swapnil, Sardana, Vijay, Bhushan, Bharat, Maheshwari, Dilip, Goyal, Ravi, Pankaj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9540964/
https://www.ncbi.nlm.nih.gov/pubmed/36211189
http://dx.doi.org/10.4103/aian.aian_1083_21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9540964/
https://www.ncbi.nlm.nih.gov/pubmed/36211189
http://dx.doi.org/10.4103/aian.aian_1083_21

Ejemplares similares